ROLE OF METABOLIC DYSFUNCTION IN ADVANCED PROSTATE CANCER
RESEARCHER PROFILE
Dr Jennifer Gunter (Filmed March 2024)
Senior Research Associate (Cancer Metabolism),
Australia Prostate Cancer Research Centre – Queensland (APCRC-Q) & Group Leader, Cancer Metabolism Group,
Translational Research Institute (TRI),
Queensland, Australia
Dr Jennifer (Jenni) Gunter is a mid-career researcher, with a metabolic research background spanning almost 15 years. She leads a research team examining the metabolic plasticity of cancer cells with the aim of identifying therapeutic targeting strategies that extend patient survival. Jenni completed her PhD in 2005 at the Oxford Centre for Diabetes, Endocrinology and Metabolism at Oxford University.
She returned to Australia in 2006 with a University of Queensland Postdoctoral Fellowship at the UQ Diamantina Institute to pursue studies into the turnover and metabolism of adipocytes in obesity.
In 2010, Jenni joined the Institute of Health and Biomedical Innovation, at QUT to research the intersection between chronic metabolic disorders and their emerging relationship to cancer. These studies were focused on the role of insulin and the relationship between the insulin and androgen signalling axes.
Dr Gunter was drawn to the area of prostate cancer research and the intersection between chronic metabolic disorders and their emerging relationship to cancer. Her strengths include expertise in the metabolic syndrome, insulin signalling and metabolism, and she has a demonstrated record of successful and productive research projects in metabolic research where she now applies her efforts to understanding the role of metabolic dysfunction in advanced prostate cancer.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Corneal and Ocular Surface Immunology and Regeneration
Assoc Professor Holly Chinnery’s career in ocular immunology began with a focus on animal models; however, it has recently transitioned into clinical imaging studies involving human research participants. The ability to visualise the immune system and sensory nerves in the human cornea represents a significant advantage in corneal immunology and neuroimmunology research.
-
Stem cells used for age-related macular degeneration
Dr. Jenna Hall is a passionate and accomplished biologist with expertise in induced pluripotent stem cell (iPSC) culture, disease modelling, and high-throughput automated systems. She recently earned her PhD from the University of Melbourne, where her research focused on using iPSC-derived retinal pigment epithelium (RPE) cells to study age-related macular degeneration. Dr Hall’s technical skillset spans manual and automated cell reprogramming and differentiation, quantitative microscopy-based phenotyping, and large scale -omics analysis.
